Informal Meeting of Health
Ministers on 10 and 11
September 2018
Regulatory and policy-related challenges in securing
supply of centrally authorised medicines
Austrian Presidency of the Council of the European Union 2018 EN
Background and Presentation of the Topic
Not least since the Council conclusions on "Innovation for the benefit of patients"1
were adopted under the Italian Presidency in 2014, access to innovative medicines
has been a recurrent theme on the agenda of Council Presidencies. In 2016, under
the Dutch Presidency, a strong focus was placed on access to innovative
medicines and their affordability2;3. The Maltese Presidency in 2017 highlighted the
benefits of exchanging information on pricing and reimbursement of medicines
between Member States4. Over the past two years, the subject has gained
additional momentum through discussions at the international level, building, for
instance, on the report adopted by the UN High Level Panel on Access to
Medicines5, the meeting of the WHO Fair Pricing Forum in May 20176, the OECD
Health Ministerial in January 2017, and most recently by the report of the Expert
Panel on effective ways of investing in Health, appointed by the European
Commission7.
One of the reasons for this growing awareness of the topic of “access to innovative
medicines and their affordability” is a significant increase in spending for high-
priced medicines, particularly in the hospital sector8.
This increase in spending means that health financing systems are coming under
growing pressure to sustainably maintain the high quality of care in Europe. When
it comes to availability of innovative medicines, we are increasingly witnessing
differences between Member States9. In addition, evidence from recent studies
shows that many newly authorised drugs do not provide any (additional) patient-
relevant benefit10;11;12.
A patient-centered European medicines policy must seek to strike a balance
between demand-driven promotion of innovation and ensuring the financial
sustainability of health systems while providing the best possible care for patients.
Pharmaceutical policy interventions to be used in this context range from regulatory
tools (i.e. in the area of drug approval), promotion of innovation, requirements for
inclusion in national reimbursement systems, to pricing, availability, financing,
access and responsible use of medicines.
In order to achieve this goal and advance the process on the political level, it is
necessary to adopt a more specific approach in the general debate. It is thus
1
Council of the European Union, Council conclusions on innovation for the benefit of patients (Brussels 2014).
2
As stated in the Council Conclusions adopted under the Dutch Presidency:“Explore possible synergies between the work of
regulatory bodies, HTA bodies and payers, whilst respecting their specific responsibilities in the pharmaceutical chain and fully
respecting Member States competences, in order to ensure timely and affordable access of patients to innovative medicinal
products that reach the market especially through EU regulatory tools of accelerated assessment, marketing authorisation in
exceptional circumstances and conditional marketing authorisation while also analysing the effectiveness of these tools and
examining possible clear and enforceable (pre-) conditions and exit options for the products that enter the market through these
mechanisms in order to ensure high level of quality, efficacy and safety of the respective medicinal product“ (Council of the
European Union 2016).
3
Ministry of Health Welfare and Sport. Summary of Medicines Plan (The Hague 2016).
4
Council conclusions on Encouraging Member States-driven Voluntary Cooperation between Health System, 16 June 2017.
5
United Nations, Report of the United Nations Secretary-General’s High-Llevel Panel on Access to Medicine, 2016.
6
World Health Organization, Report on the Fair Pricing Forum, 2017.
7
EXPH (Expert Panel on effective ways of investing in Health), Opinion on Innovative payment models for high-cost innovative
medicines, 2017.
8
OECD, 2015.
9
Panteli, D. et al. (2016).
10
Davis, C. et al. (2017).
11
Grössmann, N., Wild, C. (2016).
12
Light, D., Lexchin, J. (2012).
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 2 of 11
Austrian Presidency of the Council of the European Union 2018 EN
absolutely essential to develop and implement regulatory measures that are within
the scope of health policy. This is precisely what this informal meeting seeks to
facilitate. To this end the focus of discussions is placed on the interaction between
regulatory mechanisms and other elements of pharmaceutical policy. Based on
dialogue between market authorisation agencies and health ministries, the goal is
thus to identify and implement relevant and concrete measures.
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 3 of 11
Austrian Presidency of the Council of the European Union 2018 EN
Challenges and Possible Solutions
In the following section, four selected challenges in European medicines approval
and possible solutions are presented. The explanations are restricted to challenges
and solutions that lie within the Member States’ scope of responsibility and can
therefore be described as regulatory challenges. The focus of the discussion is on
issues at the interface between approval authorities and national health systems.
Aspects that also affect access to affordable pharmaceuticals, but go beyond this
regulatory scope have thus not been included (such as parallel imports and
reference pricing systems, for instance). The goal is to facilitate a targeted and
solution-oriented discussion in the context of this informal meeting.
Challenge 1: Optimising the exchange of information
Currently, exchange of information between approval authorities – i.e. the
European Medicines Agency (EMA) and national authorities – and payers is often
unstructured. This leads to an information deficit on the part of payers: today
payers, for instance, do generally not know which active substances are likely to be
approved within the foreseeable future, which often leads to planning uncertainties
as it is impossible to predict costs that may suddenly arise for individual medicines.
A possible solution that is currently discussed in this context is "horizon scanning".
This refers to the systematic monitoring of known trends and the identification of
new, relevant developments in the pharmaceutical market. Currently, individual
institutions undertake “horizon scanning” at the national level. There is, however, a
lack of transnational cooperation and comprehensive exchange with the approval
authorities in this respect. Although the EMA publishes a monthly list of proprietary
medicinal products that are currently in the approval process13, extensive horizon
scanning would, however, require sharing of information about the products in the
pipeline.
Regulation (EU) 536/2014, which came into force in June 2014, will lead to the
establishment of a EU database by the EMA, thus resulting in a higher level of
transparency. It is scheduled to be operational by late 2019 at the earliest.
According to the regulation, this database will contain all the data and information
transmitted via the EU portal. This includes, among other things, all documents
related to the approval procedure, notifications of the start and of the end of the
clinical trial in each Member State, notification of any temporary suspension or
restart, as well as of a temporary halt or early termination of the clinical trial. Of
particular importance is the obligation to publish a summary of the results of the
clinical trial within one year of its termination. The obligation to publish trial/study
results is independent of the outcome of the clinical trial, i.e. it also includes
negative results.
Despite these extensive transparency regulations, there is a lack of key information
that is of the utmost importance to the payer. Currently, for example, the "marketing
status" ascertained by the EMA pursuant to Article 13 (4) of Regulation (EC)
13
European Medicines Agency, Medicines under Evaluation.
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 4 of 11
Austrian Presidency of the Council of the European Union 2018 EN
726/2004 is not published. This includes, for example, the dates for the actual
placing on the market of individual medicines in the Member States.
Asymmetry of information also relates to the fact that there are no mechanisms in
place to disclose pricing models or the level of research and development
expenditures. Such disclosure is often hampered by confidentiality clauses.
Furthermore, the actual financial scale of the awarded public research funding is
also unknown. It could, for instance, be conceivable to access this data in the
context of the authorisation procedure and based on the relevant legal framework.
Information on the amount of public money spent on the development of a
medicinal product is relevant insofar as it would enable a better distribution of
public money or using the the public's contribution as an argument with respect to
pricing.
Challenge 2 : Strengthening patient benefit of newly
authorised medicinal products
Criticism voiced by payers in the context of discussions on access to high-priced
and innovative medicines often highlights that the evidence criteria required to
prove the newly authorised medicines’ patient benefit14 would often not suffice. It is
stated that such a risk relates particularly to accelerated authorisation procedures.
Based on the example of oncology medicines, several studies have shown that
only some of the newly authorised medicinal products actually provide patient
benefit with respect to prolonging patients’ lives or improving patients’ quality of life.
Moreover, the aspects life extension and quality of life are not assessed as a
mandatory requirement in the course of authorisation studies. A study published in
2017, for instance, showed that only half of the approvals granted for cancer
therapies between 2009 and 2013 (a total of 48 medicinal products for 68
indications) actually had proven life-prolonging effects. An improvement in patients’
quality of life was only demonstrated in seven out of the 68 approvals15. The
Austrian Ludwig Boltzmann Institute for Health Technology Assessment came to
similar conclusions. It showed that only 55% of the cancer medicines indications
approved between 2009 and 2016 demonstrated an overall survival benefit, in only
16% the survival benefit exceeded three months. For 27% of the approved
indications, no data on life extension was available16. A study published by Davis et
al. in 2017 showed that even three years after they had been placed on the market
33 out of 39 authorised products failed to provide evidence for an improvement in
patients’ quality of life or overall survival.
Currently, there is, moreover, a notable gap between the evidence criteria defined
for marketing authorisation and those for taking reimbursement and pricing
decisions at national level. While reimbursement decisions are based on the
evaluation of the added therapeutic benefit compared to the respective standard
therapy, approval procedures require either proof of benefit compared to placebo or
at least non-inferiority to the standard therapy.
14
Davis, C. et al. (2017); Grössmann, N., Wild, C. (2016); Light, D., Lexchin, J. (2012).
15
Davis, C. et al, (2017).
16
Grössmann, N., Wild, C. (2016).
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 5 of 11
Austrian Presidency of the Council of the European Union 2018 EN
An increase or expansion of the evidence criteria required for the approval of new
medicinal products could ensure that additional patient-relevant outcomes are to be
measured in the context of the approval process. Especially when assessing the
granting of conditional marketing authorisations, a review of the necessary
evidence criteria should be mandatory. At approval level, mechanisms should be
put in place to guarantee that comprehensive proof of evidence is submitted after
authorisation has been granted17. In its report on "Innovative payment methods for
high-priced medicines", the European Commission's expert panel on "effective
ways of investing in health" proposes the following measures with a view to
improving evidence criteria and ensuring patient benefit: Firstly, approval
procedures should include mandatory superiority studies that compare new
substances with the current therapy standards and with active comparators instead
of with placebos; secondly, outcomes that are verifiably relevant for patients be
should be used by default and, thirdly, in the context of conditional approval
procedures evidence criteria should be subject to more extensive review and
scrutiny, and it should be ensured by way of monitoring that evidence which had
not been submitted during the approval procedure or was lacking is submitted after
approval had been granted18.
Challenge 3: Ensuring the availability of innovative therapies
across Europe
Since 1995, the EMA/EC has been given the possibility of granting a single
marketing authorisation for human and veterinary medicinal products covering the
whole European Union/EC market. In addition to uniform European quality control
standards, this enables producers to launch approved medicines in all Member
States of the European Economic Area at the same time. Some indications require
a mandatory centralised authorisation procedure (such as cancer, autoimmune
diseases and rare diseases). The centralised approval process was created to
ensure fast and secure access to new therapies for patients across Europe.
Despite the fact that the vast majority of innovative medicines are centrally
approved, there are strong timing differences in the availability of new medicines
between the EU Member States. This includes significantly deferred market
launches in some Member States, averaging up to two years after the granting of
authorisation19. A fact that was also highlighted in the June 2016 Council
conclusions. In some cases, approved active substances have not been launched
at all20.
Under Regulation (EC) 726/2004, Article 14 stipulates as “sunset clause” that any
authorisation which is not followed by the actual placing of the medicinal product on
the Community market within three years after authorisation shall cease to be valid,
the same holds true for an authorised product that has not been present on the
market for three consecutive years21;22. Availability on the Union market was
17
Ludwig, W.-D. (2016)
18
EXPH (2017).
19
Panteli, D. et al.(2016).
20
WHO Reginal office for Europe, 2016
21
Art. 14 (4) Any authorisation which is not followed by the actual placing of the medicinal product for human use on the
Community market within three years after authorisation shall cease to be valid. (5) When an authorised medicinal product
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 6 of 11
Austrian Presidency of the Council of the European Union 2018 EN
interpreted by the European Commission as marketing in at least one Member
State of the European Economic Area (EEA)23. This does therefore not create a
supply requirement for the whole Union market.
A stricter interpretation of Article 14, namely that availability in just a single Member
State would not suffice, could provide an additional incentive to speed up the
market launch of authorised medicinal products in Europe. In addition, publication
of the data on "marketing status", which is ascertained in line with Article 13 (4) of
Regulation (EC) 726/2004 and reflects the status and dates of the actual placing on
the market, could contribe towards increasing pressure regarding the effective
fulfillment of supply needs.
Challenge 4: Ensuring targeted use of the orphan regulation
With a view to promoting the development of therapies for the treatment of rare
(orphan) diseases in the European Union, a procedure for the designation as
orphan medincial products was introduced. This designation can be obtained for
new medicines used to treat rare diseases. A disease is considered rare when it
affects less than 5 in every 10,000 patients in the European Union. The reason for
developing this designation was that the small number of patients suffering from
rare diseases offered little prospect of profit and thus little incentive to expedite the
necessary investments24. The orphan designation creates incentives for producers,
including reduced fees payable to the EMA for approval. In addition, the therapeutic
area of application will be protected against further approvals or extensions of
existing authorisations for ten years after the granting of the orphan designation.
This protection may, however, be reduced to six years, for instance if the producer
fails to meet his delivery obligations, if sufficient profitability can already be
demonstrated, or if an applicant can prove that a new product is safer or more
effective than the protected product. Furthermore, the EMA also provides protocol
assistance to advise producers in the development and approval processes25.
Within the first ten years of the regulation’s applicability, 63 medicinal products
were granted approval as orphan drugs for the treatment of 46 rare diseases26.
The fact that it is possible to extend therapeutic applications for active substances
with orphan designation at any time without a new authorisation procedure, is often
a topic for discussion. The active substance may be used for a much larger patient
population than originally indicated in the application for orphaned marketing
authorisation. The revenues thus generated also cast doubts on such products
eligibility for favourable financial treatment, i.e. reduced fees and fewer
requirements to be met during the authorisation process27;28. It is to be ensured that
in such a case the orphan designation should be reviewed.
previously placed on the market is no longer actually present on the market for three consecutive years, the authorisation shall
cease to be valid.
22
European Medicines Agency, European Medicines Agency post-authorisation procedural advice for users of the centralised
procedure (2018).
23
European Commission, Volume 2A Procedures for marketing authorisation Chapter 1 Marketing Authorisation (2016).
24
VO (EG) 141/2000.
25
European Commission, Orphan Medicinal Drugs.
26
Joppi, R., Garattini, S. (2013)
27
Ferner, R. E., Hughes, D. A. (2010).
28
Simoens, S. (2011).
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 7 of 11
Austrian Presidency of the Council of the European Union 2018 EN
In order to counteract such developments it could in certain cases become easier
to to withdraw such a product’s orphan designation and to withdraw the designation
earlier than originally provided for in the regulation. Any withdrawal of an orphan
designation based on the product’s verifiable high profitability would, however,
require clearly defined caps. Active ingredients that are orphaned for multiple
indications could also be grouped together when reviewed, regardless of
profitability and the number of indications awarded with respect to patients treated.
To this end, it would be necessary to define clear criteria for regular and rigorous
evaluation and verification of compliance.
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 8 of 11
Austrian Presidency of the Council of the European Union 2018 EN
Overview
Challenge Possible solutions
Challenge 1: Optimizing the exchange of information
Information deficit on the part of the payers
Horizon Scanning/the EMA provides
with respect to the products that are about to
information on products in the pipelines
be launched on the market
Inquiring on research and development
Lack of information on drug pricing as well as
costs as well as the use of public funds
(public) money spent on research and
within the scope of the authorisation
development
process
Challenge 2: Strengthening patient benefit of newly authorised medicinal
products
Accelerated approvals of medicines Improving evidence criteria: fulfillment of
(“adaptive pathways”) or conditional the necessary minimum evidence
marketing authorisation with missing or requirements is subject to stricter review,
insufficient evidence on patient benefit and stricter monitoring of evidence submission
patient safety in the case of conditional approval
procedures
Improving evidence criteria: validated,
Authorisation of medicines with little evidence additional provision of patient-relevant
of patient benefit endpoints during market approval
procedures
Different requirements for evidence required Improving evidence: comparative studies
for the drug’s approval and the subsequent using active comparators and standard of
HTA assessment care; superiority studies
Challenge 3: Ensuring the availability of innovative therapies across Europe
Stricter interpretation of the sunset clause
and stricter interpretation of the post-
approval supply requirement
Deferred or missed market launches of
approved medicinal products in certain Publication of data on the actual placing
European markets on the market of authorised medicinal
products
Challenge 4 Ensuring targeted use of the orphan regulation
Regular and structured monitoring of
Disincentives in the orphan regulation and compliance with designation requirements
opportunities of broader interpretation of the
orphan regulation Definition of clear exclusion criteria and
caps
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 9 of 11
Austrian Presidency of the Council of the European Union 2018 EN
Questions and topics for discussion
during the Informal Council
1) A key factor in ensuring access to innovative therapies is effective
interaction between the regulatory authorities and the payers, or
reimbursement authorities respectively. In recent years, measures have
been taken which have significantly improved transparency, for example by
establishing accessible databases. In which areas do you see a further
need to improve this cooperation in the future?
2) Available studies suggest that some innovative, high-priced drugs have little
evidence at the time of approval and that patient benefit is not well known.
How can the need for objectified information on the therapeutic benefit of a
new drug be ensured through the authorization procedures?
3) The EU has legislation to ensure the availability of innovative therapies
across Europe. Nevertheless, there are differences in the timing of market
entry within the member states, especially for innovative and mostly high-
priced medicines. In your opinion, what would be the appropriate measures
to ensure a balanced supply of these medicines throughout the EU?
4) The EU has taken measures to ensure the development of drugs for rare
diseases. For this purpose, incentives for so-called orphan drugs have been
established. However, with the possibility of expanding the indication of
approved products without a new orphan labeling procedure and thus
making them suitable for a larger patient population, the original intention is
often thwarted. In your opinion, what measures would be appropriate to
correct this development?
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 10 of 11
Austrian Presidency of the Council of the European Union 2018 EN
Literature
Council of the European Union. Council conclusions on innovation for the benefit of patients. 6 December 2014.
Available from: https://publications.europa.eu/en/publication-detail/-/publication/3cdb3832-7d21-11e4-97c9-
01aa75ed71a1/language-en (accessed June 2018).
Council of the European Union. Council conclusions on strengthening the balance in the pharmaceutical systems
in the EU and its Member States. 17 June 2016. Available from: http://www.consilium.europa.eu/press-releases-
pdf/2016/6/47244642812_en.pdf (accessed June 2018).
Council of the European Union. Council conclusions on Encouraging Member States-driven Voluntary Cooperation
between Health System. 16 June 2017. Available from: http://data.consilium.europa.eu/doc/document/ST-10381-
2017-INIT/en/pdf (accessed October 2017).
Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., Aggarwal, A. (2017). Availability of evidence of benefits
on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective
cohort study of drug approvals 2009-13. bmj, 359, j4530.
Ferner, R. E., Hughes, D. A. (2010). The problem of orphan drugs. BMJ, 341, c6456.
European Medicines Agency, Medicines under Evaluation.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/document_listing/document_listing_000349.jsp&
mid=WC0b01ac05805083eb (accessed June 2018).
European Medicines Agency, Regulatory Procedural Guidelines, 2009
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC5000
03981.pdf (accessed June 2018).
European Medicines Agency, European Medicines Agency post-authorisation procedural advice for users of the
centralised procedure, 2018. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC5000
03981.pdf (accessed June 2018).
European Commission, Orphan Medicinal Drugs. Available at: https://ec.europa.eu/health/human-use/orphan-
medicines_en (accessed June 2018).
European Commission, Volume 2A Procedures for marketing authorisation Chapter 1 Marketing Authorisation.
Brussels; 2016. Available at:
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol2/vol2a_chap1_rev6_201612.pdf (accessed June
2018).
EXPH (Expert Panel on effective ways of investing in Health). Opinion on Innovative payment models for high-cost
innovative medicines, 2017; European Union. Available at: https://ec.europa.eu/health/expert_panel/ (accessed
June 2018).
Grössmann, N., Wild, C. (2016). Between January 2009 and April 2016, 134 novel anticancer therapies were
approved: what is the level of knowledge concerning the clinical benefit at the time of approval?. ESMO open, 1(6),
esmoopen-2016.
Joppi, R., Garattini, S. (2013). Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the
EU. European Journal of clinical pharmacology, 69(4), 1009-1024.
Light, D., Lexchin, J. (2012). Pharmaceutical R&D What do we get for all that money?. BMJ, 345(7869), 22-25.
Ludwig, W. D. (2016). Zulassungsverfahren für neue Arzneimittel in Europa. In Arzneiverordnungs-Report 2016
(pp. 29-47). Springer, Berlin, Heidelberg.
Ministry of Health Welfare and Sport (2016). Summary of Medicines Plan. The Hague; Available at:
http://english.eu2016.nl/binaries/eu2016-en/documents/publications/2016/03/1/summary-of-medicins/summary-of-
medicines-plan.pdf (accessed June 2018).
OECD (2015), “Pharmaceutical spending trends and future challenges", in Health at a Glance 2015: OECD
Indicators, OECD Publishing, Paris, https://doi.org/10.1787/health_glance-2015-5-en.
Panteli, D., Arickx, F., Cleemput, I., Dedet, G., Eckhardt, H., Fogarty, E., Kaitelidou, D. (2016). Pharmaceutical
regulation in 15 European countries. Health systems in transition, 18(5), 1-118.
Simoens, S. (2011). Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet
journal of rare diseases, 6(1), 42.
United Nations (2016), Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicine.
Available at:
https://static1.squarespace.com/static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/147389003132
0/UNSG+HLP+Report+FINAL+12+Sept+2016.pdf (accessed June 2018).
World Health Organization (2017), Report on the Fair Pricing Forum 2017. Available at:
http://www.who.int/medicines/access/fair_pricing/FairPricingForum2017MeetingReport.pdf?ua=1 (accessed June
2018)
Informal Ministers HEALTH - 10 and 11 September 2018
Challenges in Medicines Regulation Page 11 of 11
Informal Meeting of Health
Ministers on 10 and 11
September 2018
Investment in Digital Health
Austrian Presidency of the Council of the European Union 2018 EN
Background and Challenges
In recent years, there has not been a single health policy conference that has not
highlighted the central importance of digitalisation in the healthcare sector. The
health ministers first expressed the importance of this issue in the EU Council in
2009 under the Swedish Presidency in the Council Conclusions on “Safe and effi
cient healthcare through eHealth1 and more recently under the Estonian Presiden
cy in December 2017 in the Council Conclusions on “Health in the digital society”2.
Similar documents have repeatedly been adopted by the European Parliament3. In
the context of the overall objectives of a Digital Single Market, the European Com
mission has on many occasions and most recently in April 2018 emphasized the
strategic importance of the health sector in a separate Communication4.
It is without doubt that the provision and use of personal digital health data in the
diagnosis and treatment of illness are in the public interest. Today, anyone who
wants to ensure the focus is on the patient within the health system cannot achieve
this without digitalisation. Every single member of the healthcare profession, be it in
the field of medicine or other nursing care, is better supported in fulfilling their re
sponsible role through the use of digital health data: knowing more about the pa
tients in their care enables them to provide a better diagnosis, treatment or care.
In 2012, the Austrian parliament, for example, explained this public interest in its
Health Telematics Law as being based on the fact that the use of health data leads
to improved and faster availability of medical information, which in turn contributes
to higher quality therapeutic decision-making and treatment as well as to an in
crease in the process and performance quality of health services. The expansion of
integrated forms of healthcare would not be possible without such digital data ex
change5.
1
Council Conclusions of 1 December 2009 on safe and efficient healthcare through eHealth (OJ C
302,12.12.2009, p. 12).
2
Council Conclusions of 8 December 2017 on health in the digital society – making progress in data-
driven innovation in the field of health (OJ C 440, 21.12.2017, p. 3).
3
See, for example, the resolution of the European Parliament of 19 May 2015 on safer healthcare in
Europe: improving patient safety and fighting antimicrobial resistance (P8 TA[2015]0197), in which the
EP calls for strengthening of the possibilities provided by eHealth for improving patient safety includ
ing via electronic patient records and exploring the instruments of mobile health services and the
cooperation between Member States towards exchange of experience and know-how.
4
Commission Communication to the European Parliament, the Council, the European Economic and
Social Committee and the Committee of the Regions on enabling the digital transformation of health
and care in the digital single market, citizen empowerment and building a healthier society,
COM(2018) 233 final of 25.4.2018.
5
See § 13 Para.1 of the Austrian Federal Law on data protection measures in the processing of elec
tronic health data and genetic data (Health Telematics Law 2012 – GTelG 2012) StF: BGBl. I No.
111/2012.
Informal Ministers HEALTH - 10 and 11 September 2018
Investment in Digital Health Seite 2 von 6
Austrian Presidency of the Council of the European Union 2018 EN
Both politically and legally it is undisputed that citizens have a right to access their
own personal health data6. This principle is not achievable without digitalisation.
Furthermore, the provision and use of digital health data are also of enormous sig
nificance for research and science. This is, of course, particularly true in the medi
cal and nursing fields but also indeed in terms of gaining a better understanding of
the functioning and efficiency of complex health systems. Without the consideration
and evaluation of health data, an increase in both process and performance quality
as well as in organisational and economic efficiency is inconceivable.
Of course, the Member States of the European Union are by no means at the be
ginning in the field of eHealth – or digital health. Today, for example, modern labor
atory or diagnostic imaging is unimaginable without digitalisation. Internal process
es as well as out-patient and in-patient healthcare providers are for the most part
IT-based. Also in the area of patient documentation or invoicing electronic support
systems have long become indispensable. There are also promising applications in
the field of telemedicine, telemonitoring and directed communication between indi
vidual healthcare providers.
The Member States have found ways and means to develop cross-border
healthcare co-operation. The eHealth Network7 is working on the legislative frame
work of Directive 2011/24 EU on the principles for an interoperable eHealth Eco-
System in the EU. Initial Guidelines for an EU Interoperability Framework, data sets
for a Patient Summary or for electronic prescriptions are, for example, already
available.
With funds from the Connecting Europe Facility, initial concrete applications are
already being developed for a European eHealth Digital Service Infrastructure
(eHDSI). Here again there is a jointly agreed procedure.
Several of the relevant competent authorities in the Members States already came
together with a range of other stakeholders under the Estonian EU Council Presi
dency in October 2017 to form the initiative “The Digital Health Society”8.
6
In political terms, pursuant to Commission Communication of 25.4.2018 (FN 4), which focuses on:
citizens‘ secure access to and sharing of health data across borders. General Data Protection Regu
lation in force since May 2018 forsees, for example, the data subject’s right of access to information
(Article 15) and a right to data portability (Article 20).
7
Article 14 of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011
on the patient rights to cross-border healthcare (OJ L 88 of 4.4.2011, p. 45).
8
https://echalliance.com/page/digitalhealthsociety (retrieved 03.07.2018)
Informal Ministers HEALTH - 10 and 11 September 2018
Investment in Digital Health Seite 3 von 6
Austrian Presidency of the Council of the European Union 2018 EN
Challenges and Possible Solutions
The discussions of the Health Ministers at this Informal Meeting in Vienna should
focus less on the principles and the necessity for digitalisation of the healthcare
systems. They should not only acknowledge progress already made.
Meanwhile, the European legislative framework has been significantly improved
with the General Data Protection Regulation9, the eIDAS Regulation10 and the NIS
Directive11.
The Health Ministers are therefore invited to discuss jointly with the Commission
the concrete steps needed for overcoming what are indisputably still existing barri
ers and which stand in the way of fulfilling the potential of making full use of digital
data in the health sector. Although there are already ways and means of exchang
ing personal diagnostic data with the aim of ensuring continuity of treatment and
care, or making health data available for example in registers for medical research
purposes, we are still a long way away from a situation where such data exchange
takes place comprehensively in all areas of the various healthcare systems.
Insufficient use is being made of the potential for digital data exchange in the health
sector12.
Public health systems are indeed committed to data exchange as a clear goal with
the aim of optimization of quality of care. Yet large parts of the actually existing
digital infrastructure in the healthcare system – in particular medical software used
by doctors working in general practice but also in many hospital information sys
tems – is not or is only to a very limited extent suitable for data exchange outside of
a specific organisation.
Until these barriers to a truly interoperable infrastructure – for example in the area
of standards, formats, comparability, reliability, accessibility etc. – have been over
come, many of the proclaimed goals to optimize quality of care or in research will
ultimately not be attainable.
9
Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the
protection of natural persons in the processing of personal data, on free movement of data and on the
repeal of Directive 95/46/EG (Data Protection Basic Regulation) (OJ. L 119 of 4.5.2016, p. 1).
10
Regulation (EU) Nr. 910/2014 of the European Parliament and of the Council of 23 July 2014 on
electronic identification and trust services for electronic transactions in the single market and on the
repeal of Directive 1999/93/EG (OJ L 257 of 28.8.2014, p. 73).
11
Directive (EU) 2016/1148 of the European Parliament and of the Council of 6 July 2016 on
measures for ensuring a high level of security of network and information systems across the Union
(OJ L 194 of 19.7.2016, p. 1).
12
See para. 22 of the Council Conclusions of 8 December 2017 (FN 2), where it is emphasized that
“the removal of barriers for the stronger use of the potential of digital health and of the potential of
digital healthcare and internet-supported care calls for a comprehensive package of measures, which
build on the opportunities of the digital single market and the principle of free movement of data as
well as the principles in accordance with the EU eGovernment Action Plan”.
Informal Ministers HEALTH - 10 and 11 September 2018
Investment in Digital Health Seite 4 von 6
Austrian Presidency of the Council of the European Union 2018 EN
This is, however, the key point: health data is predominantly generated in out-
patient care facilities and in hospitals. What needs to be done in terms of meeting
the overall goals of the health system is ultimately to focus on the numerous indi
vidual “data generators” to bring them up to date with a new generation of infra
structure to make them fit for the age of digital health.
As there is, however, a strong public interest in the exchange of health data, public
funding also needs to actively support the interoperability of private and public
healthcare facilities via the financing of digital infrastructure. Achieving this interop
erable eco-system in the healthcare sector will not be possible without the incentive
provided by public funding.
Overall, in Europe we need a significantly renewed and harmonized digital infra
structure on the level of actual out-patient and in-patient healthcare facilities. This
must be established in a comprehensive manner and not only project-based as this
would not ensure the same level of access for as many patients as possible.
Financing instruments recently proposed by the Commission such as, for example,
the “Digital Europe” programme13, indeed include what is – compared with previous
documents – a more detailed description of the issues involved, but do not yet put
forward suggestions for concrete measures for dealing with them. Detailed work
still needs to be done towards developing a transparent and well-coordinated
health policy strategy in line with the needs of healthcare providers, which can also
be defended against other policy areas.
It is thus, as a matter of urgency, that Health Ministers of the Member States and
the Commission are therefore urged to keep to their repeated political declarations
of intent and concessions14 by reaching agreement of concrete measures, which
ensure and implement better use of EU funding in the support of interoperability of
digital infrastructure in the healthcare sector.
13
Proposal for a Regulation of the European Parliament and the Council on the setting up of the “Digi
tal Europe” programme for the period 2021–2027, COM(2018) 434 final of 6.6.2018.
14
See in particular para. 50 of the Council Conclusions of 8 December 2017 (FN 2) in which the
Member States and the Commission are requested to, “make better use of Union funding mecha
nisms such as the European Fund for Strategic Investments (EFSI), the EU Structural Funds, the
Connecting Europe Facility and Horizon2020 to support large-scale digital health implementation, by
improving synergies in the cost-efficient use of EU and national funds and identifying common priori
ties and investment needs, and develop appropriate funding mechanisms and incentives to support
interoperability of digital health infrastructure”. In its Communication of 25.4.2018 (FN 4) the Commis
sion also noted it will “encourage the support of digital eHealth services infrastructure” and highlighted
the need for the mobilisation of various financing resources as well as innovative awarding of con
tracts and investment possibilities.
Informal Ministers HEALTH - 10 and 11 September 2018
Investment in Digital Health Seite 5 von 6
Austrian Presidency of the Council of the European Union 2018 EN
Issues and Discussion Topics for the In
formal Meeting
Austria as an active holder of the Presidency regards itself bound to contribute to
wards concrete proposed solutions. In this spirit and based on the Conclusions of
the Council of December 201715, the Health Ministers will be asked at this Informal
Meeting,
1. if a European-wide catalogue of necessary requirements, standards and
formats should be agreed on with a view to developing a digital infrastruc
ture that covers the largest possible number of in-patient and out-patient
health care providers and is interoperable both at European and at national
level;
2. if the above-mentioned eHealth Network in cooperation with the respec
tive Directorates-General of the Commission and based on such a cata
logue should submit by mid-2019 a specific guideline for targeted Europe
an-wide support and investment programmes;
3. and which priorities should, according to Member States, be considered
when developing the relevant framework conditions?
15
See para. 40. of the Council Conclusions of 8 December 2017 (FN 2) in which the Member States
and the Commission are requested to “work together, in particular within the eHealth Network, with
the aim of achieving interoperable and user-friendly health information systems, which allow connec
tivity of personal health devices and better interaction and information exchange between health care
providers and patients”.
Informal Ministers HEALTH - 10 and 11 September 2018
Investment in Digital Health Seite 6 von 6
Dear Sir or Madam,
Please forward the invitation to the respective minister.
Please do not forget to nominate a Delegation Accreditation Officer via
[email protected] as soon as possible.
Kind regards,
EU Presidency Team
E-Mail:
[email protected]
www.eu2018.at
General Information for
Delegates
Informal Meeting of Health Ministers,
10-11 September 2018, Vienna
Austrian Presidency of the Council of the European Union 2018 EN
Venue
The Informal Meeting of Health Ministers will take place on 10-11 September 2018
in Vienna at the permanent conference and media center “Austria Center
Vienna” (Bruno-Kreisky-Platz 1, 1220 Vienna). The conference center is situated
just 7 minutes from the city center by public transport.
Delegation Format
The format of the delegations is as follows:
- for the Member States and the Council Secretariat – Minister/Head of
Delegation (HoD) + 3 delegates (incl. the Health Attaché),
- for the European Parliament, European Commission services, EFTA countries
and other organisations – Head of Delegation (HoD) + 2 delegates.
For the invitation regime please see the section on accommodation.
Accreditation
The designated Delegation Accreditation Officers (DAOs) nominated by the
delegations will receive an email inviting them to register their delegation in the
accreditation system of the Austrian EU Presidency.
Online accreditation will be open from 26 July until 17 August 2018.
Queries relating to accreditation should be sent to
[email protected], all
other questions should be directed to
[email protected].
For security reasons, delegates will only be admitted into the conference center
upon presentation of a valid admission badge or pin, which will be distributed by
the assigned Liaison Officer upon arrival. Badges are non-transferable and
delegates are requested to keep the badges visible. In case of loss, please kindly
report it to the conference organiser immediately.
National Security Officer(s) / Firearms Request
Any national security officers accompanying Heads of Delegation shall be
registered by the Delegation Accreditation Officer in the online accreditation
system.
For further information concerning security officers carrying firearms, please
contact
[email protected].
General Information for Delegates Page 2
Austrian Presidency of the Council of the European Union 2018 EN
Presidency Portal for Informal Events (PPI)
As Austria intends to organise a paper-free presidency, there will be no printed
documents at the meeting venue. All relevant information will be provided via the
Presidency Portal for Informal Events (PPI).
Every participant will receive an automated email containing a link to the
Presidency Portal for Informal Events (PPI) upon successful accreditation.
Travelling and Transport
Arrival and Departure
The arrival and departure of Heads of Delegation and accompanying delegates
arriving by state or commercial aircraft will be handled at the General Aviation
Center (GAC) of Vienna Airport. Transportation from and to the airport will be
provided.
Heads of Delegation travelling in their own vehicles will be escorted by Austrian
police after entering and before leaving Austrian national territory. Delegations are
requested to communicate the respective border crossing points, as well as the
estimated date and time of the border crossing (arrival and departure) via the
accreditation system.
All Heads of Delegation and accompanying delegates leaving on a commercial
flight are requested to check in online beforehand in order to reduce waiting times
at the airport.
All other delegates travelling separately are kindly asked to organise their own
transport to and from Vienna International Airport. The closest public transport
station to the meeting venue is Kaisermühlen/VIC. The closest public transport
station to the Hotel Hilton Stadtpark is Wien Mitte/Landstraße.
Delegates attending events in Vienna are entitled to a free bus (Vienna Airport
Lines) or train ticket sponsored by the Austrian Federal Railways (ÖBB) for the
journey from Vienna International Airport to Vienna city center or the Austria Center
Vienna.
The ticket is available at the ÖBB Welcome Desk or the City Airport Train Counter
upon presentation of a notification received by delegates from the Presidency
Portal for Informal Events (PPI). The ÖBB Welcome Desk and the City Airport Train
Counter are located on the right-hand side of the arrivals hall. Please note that the
free tickets are only valid for a single journey between Vienna International Airport
and Vienna city center or the Austria Center Vienna. Tickets must be bought for
any onward journeys as well as for the return journey to the airport.
General Information for Delegates Page 3
Austrian Presidency of the Council of the European Union 2018 EN
a) Train Connections
Austrian Federal Railways (ÖBB) runs a Railjet service that connects Vienna
Airport with Vienna Hauptbahnhof (main train station) in approximately 15 minutes.
There are also direct connections to the city center using the S7 rapid transit
railway.
Single ticket: EUR 4.10 (see also above concerning the free tickets available on
arrival).
For more information, please visit www.oebb.at
b) Airport Shuttle Service
The City Airport Train (CAT) offers a direct non-stop connection between Vienna
Airport and the city center in 16 minutes (Wien Mitte train station – Bahnhof Wien
Mitte).
Single ticket: EUR 12 / Return: EUR 21 (see also above concerning the free tickets
available on arrival).
For more information, please visit www.cityairporttrain.com
c) Vienna Airport Lines
The Vienna Airport Line offers a direct bus service to various destinations in the city
center and to the meeting venue.
Single ticket: EUR 8 / Return: EUR 13 (see also above concerning the free tickets
available on arrival).
For more information please visit www.viennaairportlines.at
d) Taxis
There is a taxi stand opposite the arrivals hall’s exit at the airport. A taxi ride from
the airport to Vienna city center typically costs between EUR 40 and EUR 50.
Public Transport
Vienna has a fully integrated public transport network. From Monday to Friday, the
underground, trams and buses run from approximately 5:00 a.m. until just after
midnight.
Single ticket: EUR 2.40 / 24 hour ticket: EUR 8 / 48 hour ticket: EUR 14.10
Our multilingual mobility service eu2018 Traffic offers up-to-date traffic information
as well as a real-time intermodal trip planner for public transport, road transport and
the footpath network to all delegates, visitors and the Austrian population. The
multilingual web service is available at https://eu2018traffic.verkehrsauskunft.at or
as an app for iOS and Android.
General Information for Delegates Page 4
Austrian Presidency of the Council of the European Union 2018 EN
Transfers during the Informal Meeting of Health Ministers
All transportation in connection with the official programme will be provided by the
Presidency.
Accommodation
The Austrian Presidency has pre-booked accommodation for the Head of
Delegation + 1 delegate (the Deputy Head of Delegation) and will cover the hotel
room costs for two rooms for 1 night (10/11 of September 2018) at Hotel Hilton
Stadtpark. The Head of Delegation + 1 delegate (the Deputy Head of Delegation)
are kindly asked to confirm their stay in the designated hotel in the accreditation
system.
There will be an additional room reservation for a third delegate at Hotel Hilton
Stadtpark, but costs will not be covered by the Presidency. A certain number of
rooms with a preferential rate of EUR 179.00 (per night/room for single use) has
been reserved for this purpose at Hotel Hilton Stadtpark. If you would like to make
use of this offer, please confirm your interest by answering the corresponding
question in our online accreditation form and follow the link
https://interconvention.eventsair.com/healthministers/hotelbooking.
Furthermore, Health Attachés of the Working Party on Public Health – Attaché
level (i.e. Member States and Council Secretariat) are requested to register as
‘Delegate (Attaché)’ via the online accreditation system. Other delegates attending
the Attachés’ trip (i.e. EFTA states and European Commission/DG SANTE), one
per delegation, are requested to register as ‘Deputy head of delegation’ and
confirm their participation in the Attachés’ trip via the online accreditation system.
The Austrian Presidency has pre-booked rooms at Hotel Hilton Stadtpark and will
cover the hotel room costs for 2 nights (10/11 September: participation in the
Informal Meeting of Health Ministers; 11/12 September: participation in the
Attachés’ trip).
All other delegates are kindly requested to contact their national embassy for
room reservations, to pay for their own accommodation and to confirm their stay in
the accreditation system. If you opt for alternative accommodation, please be
aware that no direct transport will be provided by the Presidency and charges for
hotel rooms will have to be covered at your own cost.
The cost of accommodation includes breakfast as well as VAT and city tax. Please
note that any individual expenses, such as telephone use, minibar, laundry etc., are
not included in the room rate and will not be covered by the Austrian Presidency.
Therefore, you are kindly asked to settle such expenses before your departure.
If you have any queries regarding the accommodation and/or hotel reservation,
please contact
[email protected].
General Information for Delegates Page 5
Austrian Presidency of the Council of the European Union 2018 EN
Liaison Officers
A Liaison Officer (LO) will be assigned to each delegation. Contact details of the
assigned LOs will be communicated to each delegation in due course.
Languages
Interpretation services will be provided in DE, EN, FR, ES and IT during the
Informal Meeting of Health Ministers.
Interpretation services for the press conference will be provided in DE, EN and FR.
If your own interpreters will be accompanying you, please complete their
registration in the accreditation system and bear in mind that they should be
registered as delegates.
Cultural Programme and Gala Dinner
All participants are kindly invited to a cultural programme and gala dinner at 7:00
p.m. on 10 September 2018 at the Imperial Hofburg Vienna (Heldenplatz, 1010
Vienna)
Specific dietary restrictions/requirements should be indicated via the online
accreditation system.
Conference Services at the Austria Center Vienna:
Bilateral Meetings
A limited number of bilateral meeting rooms are available on Level -2 of the Austria
Center Vienna. Requests for reservations for these meeting rooms should be sent
to
[email protected].
Information Desk / IT Helpdesk / Meeting Point
An information desk has been set up in Foyer D on Level -2. Please direct any
questions regarding the meeting as well as requests for technical support to the
information desk team.
Facilities and Services
Free Wi-Fi, computers, photocopying and scanning facilities will be available.
General Information for Delegates Page 6
Austrian Presidency of the Council of the European Union 2018 EN
Medical Care
Medical assistance will be available at the conference center. The examination
room is located on Level -2 in room -2.41.
Other information:
Accessibility
The Austria Center Vienna as well as Hotel Hilton Stadtpark are fully accessible to
persons with disabilities and assistance will be provided if needed.
Austrian EU Presidency Website
The Austrian EU Presidency website (www.eu2018.at) contains information on all
topics related to the Austrian EU Presidency.
Information on Vienna
Information on Vienna and its cultural and recreational amenities is available at
https://www.wien.info/en. An interactive city map of Vienna can be found at
www.wien.gv.at/stadtplan/en/.
Currency
The official currency of Austria is the Euro. Currency can be exchanged at the
airport, in banks, or in any currency exchange office.
Visa, MasterCard, American Express and Diner’s Club cards are widely accepted.
Tap Water
We recommend drinking tap water as Vienna is proud of its high quality tap water
originating directly from the Austrian Alps.
Local Time
Austria uses Central European Time (CET), which is UTC plus 1 hour (summer
time – between March and October – is UTC plus 2 hours).
Electricity
220 volt AC (plug: two round prongs)
Smoking
Smoking is prohibited in indoor public areas.
General Information for Delegates Page 7
Austrian Presidency of the Council of the European Union 2018 EN
Dialling Codes in Austria
Austria: +43
Vienna: (0)1
Contact information
For all queries concerning this meeting, please contact
[email protected].
We look forward to seeing you in Vienna!
Unterzeichner Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumentenschutz
Datum/Zeit 2018-07-25T18:03:41+02:00
CN=a-sign-corporate-light-02,OU=a-sign-corporate-light-02,O=A-Trust Ges. f.
Aussteller-Zertifikat Sicherheitssysteme im elektr. Datenverkehr GmbH,C=AT
Serien-Nr. 738854333
Hinweis Dieses Dokument wurde amtssigniert.
Informationen zur Prüfung des elektronischen Siegels bzw. der elektronischen Signatur finden Sie unter:
http://www.signaturpruefung.gv.at
Prüfinformation Informationen zur Prüfung des Ausdrucks finden Sie unter:
https://www.sozialministerium.at/site/Ministerium/Willkommen_im_Ministerium/Amtssignatur/Amtssignatur
General Information for Delegates Page 8
Draft Programme
Informal Meeting of Health Ministers on 10 and 11
September 2018
Austrian Presidency of the Council of the European Union in 2018 Programme
Overview
Event: Informal Meeting of Health Ministers
Date, time: 10 and 11 September 2018, 12.00 - 2.00 pm
Venue: Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1, 1220 Vienna
Host: Federal Ministry of Labour, Social Affairs, Health and
Consumer Protection
Editor: The Austrian Presidency of the Council of the European
Union
Informal meeting of Health Ministers - 10 and 11 September 2018
Austrian Presidency of the Council of the European Union in 2018 Programme
Programme
Monday, 10 September 2018 (midday / afternoon)
12.00 - 1.30 pm Arrival of the participants at the ACV
Doorstep - Heads of Delegations arrive in the ACV
entrance area
Handshake - The Federal Minister welcomes the
Heads of Delegation
Buffet Lunch for all participants
1.30 - 3.30 pm Working session: Regulatory and policy-related
challenges in securing supply of centrally authorised
medicines
Welcome and introduction by Beate Hartinger-Klein
(Federal Minister of Labour, Social Affairs, Health and
Consumer Protection)
Welcome and introduction by Vytenis Andriukaitis (EU-
Commissioner for Health and Food Safety, European
Commission)
Zsuzsanna Jakab (WHO Regional Director for Europe)
Contribution: Access to medicines (tbc)
Guido Rasi (Director, European Medicines Agency)
Contribution: to be defined (tbc)
Exchange of views based on the questions raised in the
thematic background document
3.30 - 3.45 pm Coffee break
3.45 - 5.00 pm Working session: Regulatory and policy-related
challenges in securing supply of centrally authorised
medicines (continued)
Exchange of views based on the questions raised in the
thematic background document (continued)
Concluding statement by Vytenis Andriukaitis (EU-
Commissioner for Health and Food Safety, European
Commission)
Informal meeting of Health Ministers - 10 and 11 September 2018
Austrian Presidency of the Council of the European Union in 2018 Programme
Conclusion on the results of the discussion by Beate
Hartinger-Klein (Federal Minister of Labour, Social Affairs,
Health and Consumer Protection)
5.00 - 5.30 pm Family photo
from 5.30 pm Transfer to the hotel
from 6.30 pm Transfer from the hotel to the evening event venue
7.00 - 10.30 pm Cultural programme and Gala Dinner
10.30 - 11.00 pm Transfer from the evening event venue to the hotel
Tuesday, 11 September 2018 (morning / midday)
from 8.30 am Transfer from the hotel to the conference venue (ACV)
9.00 - 11.00 am Working session: Investment in Digital Health
Welcome and introduction by Beate Hartinger-Klein
(Federal Minister of Labour, Social Affairs, Health and
Consumer Protection)
Welcome and introduction by Vytenis Andriukaitis (EU-
Commissioner for Health and Food Safety, European
Commission)
Presentation by Roberto Viola (Director-General for
Communications Networks, Content and Technologies, DG
CONNECT)
Zsuzsanna Jakab (WHO Regional Director for Europe)
Contribution to be defined (tbc)
Exchange of views based on the questions raised in the
thematic background document
11.00 - 11.15 am Coffee break
11.15 - 12.30 am Working session: Investment in Digital Health
(continued)
Volker Amelung (Hannover Medical School, Institute for
Epidemiology, Social Medicine and Health Systems
Research) Contribution: The added value of digitalisation in
modern health care provision (tbc)
Informal meeting of Health Ministers - 10 and 11 September 2018
Austrian Presidency of the Council of the European Union in 2018 Programme
Exchange of views based on the questions raised in the
thematic background document (continued)
Concluding statements by Vytenis Andriukaitis (EU-
Commissioner for Health and Food Safety, European
Commission) und Roberto Viola (Director-General for
Communications Networks, Content and Technologies, DG
CONNECT)
Conclusion on the results of the discussions by Beate
Hartinger-Klein (Federal Minister of Labour, Social Affairs,
Health and Consumer Protection)
12.30 - 2.00 pm Buffet Lunch for all participants
as of 12.30 pm Transfer to the airport
According to the delegations’ needs
1.00 - 1.30 pm Press conference
Informal meeting of Health Ministers - 10 and 11 September 2018